Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

9 Meters Biopharma, Inc. (NMTR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2691+0.0051 (+1.93%)
At close: 04:00PM EDT
0.2700 +0.00 (+0.33%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2640
Open0.2650
Bid0.2700 x 800
Ask0.2720 x 900
Day's Range0.2627 - 0.2750
52 Week Range0.1970 - 1.4600
Volume1,610,315
Avg. Volume4,344,340
Market Cap68.8M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    9 Meters Biopharma to Participate in the William Blair Biotech Focus Conference 2022

    RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that John Temperato, President & Chief Executive Officer of 9 Meters, will participate in a fireside chat at the William Blair Biotech Focus Conference taking place on July 12 - 13, 2022, in New York City.

  • ACCESSWIRE

    9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome

    Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel SyndromeRALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced it has entered into a senior secured convertible notes facility with a single lender for up to $70 million that is part of an overall financing strategy to support the continued develop

  • ACCESSWIRE

    9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

    (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced positive preliminary topline results from the VIBRANT study (VurolenatIde for short Bowel syndrome Regardless of pArenteral support requiremeNT), its Phase 2 trial of vurolenatide, a proprietary, long-acting GLP-1 receptor agonist in development for the treatment of adult patients with short bowel syndrome (SBS). Based on positive results from this Phase 2

Advertisement
Advertisement